Gi-ming Lai

Taipei, TNQ, TW 
Taipei, TNQ, TW 

Overview

Gi-ming Lai practices practicing medicine in Taipei, Taiwan.

Their clinical expertise encompasses Lung Adenocarcinoma, Marginal Zone Lymphoma (MZL), Lung Cancer, and Glioblastoma.

They are actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 2 clinical trials.

Locations

Taipei, TNQ 11696, Taiwan
Other Locations
TPQ, Taiwan
Miaoli, TNQ 35053, Taiwan
Kaohsiung, KHQ 84001, Taiwan
Zhunan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery
A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery
Enrollment Status: Not_yet_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drug: BLEX 404
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-controlled, Parallel, Pilot Study to Evaluate the Quality of Life Improvement of Oral Oligo Fucoidan as an Adjuvant in Subjects Receiving Platinum-based Chemotherapy With NSCLC
A Randomized, Double-blind, Placebo-controlled, Parallel, Pilot Study to Evaluate the Quality of Life Improvement of Oral Oligo Fucoidan as an Adjuvant in Subjects Receiving Platinum-based Chemotherapy With NSCLC
Enrollment Status: Withdrawn
Publish Date: August 28, 2019
Intervention Type: Dietary supplement
Study Phase: Not Applicable
View 1 Less Clinical Trial

43 Total Publications

Drastic Synergy of Lovastatin and Antrodia camphorata Extract Combination against PC3 Androgen-Refractory Prostate Cancer Cells, Accompanied by AXL and Stemness Molecules Inhibition.
Drastic Synergy of Lovastatin and Antrodia camphorata Extract Combination against PC3 Androgen-Refractory Prostate Cancer Cells, Accompanied by AXL and Stemness Molecules Inhibition.
Journal: Nutrients
Published: September 28, 2023

Frequently Asked Questions about Gi-ming Lai

Is Gi-ming Lai a top-rated expert for Lung Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Gi-ming Lai is classified as an Experienced expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gi-ming Lai participate in research or clinical trials?

Yes. Gi-ming Lai has published 43 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Gi-ming Lai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lai's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile